KPV
About
About KPV
KPV is a tripeptide derived from the C-terminus of alpha-MSH (Lys-Pro-Val) with potent anti-inflammatory properties and direct antimicrobial activity. It is studied for inflammatory bowel disease, skin inflammation, and wound healing. Oral formulations show efficacy in gut inflammation by acting directly on intestinal epithelial cells and immune cells. It has a favorable safety profile.
Science
Mechanism of Action
Inhibits nuclear translocation of NF-κB and downregulates pro-inflammatory cytokine production (IL-6, TNF-α) in macrophages and epithelial cells; also activates melanocortin receptors to produce broad anti-inflammatory signaling.
Dosing
Typical Protocol
500 mcg–1 mg oral capsule daily for GI inflammation; 100–500 mcg subcutaneous injection for systemic use.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound is legal to prescribe and dispense through a licensed 503A or 503B compounding pharmacy with a valid prescription. It is not FDA-approved as a finished drug product, but compounding is explicitly permitted under federal law. Quality and sterility standards vary by pharmacy — look for PCAB-accredited compounders.
Evidence
Evidence Tier
Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.
Find a Verified Provider
See which Vial-verified providers offer KPV — with trust scores, legal credentials, and pricing transparency.